WO2024054806A3 - Vecteurs de salmonella typhi vivants modifiés pour exprimer des antigènes de protéines de cancer et leurs méthodes d'utilisation - Google Patents
Vecteurs de salmonella typhi vivants modifiés pour exprimer des antigènes de protéines de cancer et leurs méthodes d'utilisation Download PDFInfo
- Publication number
- WO2024054806A3 WO2024054806A3 PCT/US2023/073489 US2023073489W WO2024054806A3 WO 2024054806 A3 WO2024054806 A3 WO 2024054806A3 US 2023073489 W US2023073489 W US 2023073489W WO 2024054806 A3 WO2024054806 A3 WO 2024054806A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salmonella typhi
- methods
- engineered
- express
- subject
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 5
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 210000004379 membrane Anatomy 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 101710095678 Lipid A deacylase PagL Proteins 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des compositions et des méthodes permettant d'induire une réponse immunitaire chez un sujet dont l'état le nécessite, comprenant l'administration au sujet d'une quantité immunologiquement efficace d'un vecteur de Salmonella Typhi vivant, le vecteur de Salmonella Typhi ayant été modifié pour exprimer un ou plusieurs antigènes du cancer. Selon certains aspects, le vecteur a été modifié pour exprimer une protéine à repliement de la membrane externe Bam A ou un fragment ou un variant de celle-ci; et une désacylase modifiant le lipide A, PagL, ou un fragment ou un variant de celle-ci, ledit vecteur de Salmonella Typhi étant apte à délivrer l'antigène à un tissu muqueux ou par voie sous-cutanée à des cellules dendritiques via une vésicule de membrane externe lorsqu'il est administré à un sujet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263403833P | 2022-09-05 | 2022-09-05 | |
| US63/403,833 | 2022-09-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2024054806A2 WO2024054806A2 (fr) | 2024-03-14 |
| WO2024054806A3 true WO2024054806A3 (fr) | 2024-05-02 |
Family
ID=90191910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/073489 WO2024054806A2 (fr) | 2022-09-05 | 2023-09-05 | Vecteurs de salmonella typhi vivants modifiés pour exprimer des antigènes de protéines de cancer et leurs méthodes d'utilisation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024054806A2 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178888A1 (fr) * | 2020-03-05 | 2021-09-10 | University Of Maryland, Baltimore | Vecteurs vivants de salmonella typhi modifiés pour exprimer des antigènes de protéines cancéreuses et leurs procédés d'utilisation |
-
2023
- 2023-09-05 WO PCT/US2023/073489 patent/WO2024054806A2/fr unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178888A1 (fr) * | 2020-03-05 | 2021-09-10 | University Of Maryland, Baltimore | Vecteurs vivants de salmonella typhi modifiés pour exprimer des antigènes de protéines cancéreuses et leurs procédés d'utilisation |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024054806A2 (fr) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11065318B2 (en) | Yeast-MUC1 immunotherapeutic compositions and uses thereof | |
| US11938175B2 (en) | Yeast-brachyury immunotherapeutic compositions | |
| Cho et al. | Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects | |
| Lollini et al. | Vaccines and other immunological approaches for cancer immunoprevention | |
| CN108743937B (zh) | 疫苗组合物和方法 | |
| Chua et al. | Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2 | |
| US20210077601A1 (en) | Medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| US20230105457A1 (en) | Immunogenic Compounds For Treatment Of Adrenal Cancer | |
| CA2994272A1 (fr) | Compositions immunotherapeutiques de levure brachyury modifiee | |
| WO2024054806A3 (fr) | Vecteurs de salmonella typhi vivants modifiés pour exprimer des antigènes de protéines de cancer et leurs méthodes d'utilisation | |
| Kim et al. | High Efficacy of | |
| Galán et al. | In vivo antigen delivery by a Salmonella type III secretion system for therapeutic cancer vaccine development | |
| NZ622335B2 (en) | Yeast-muc1 immunotherapeutic compositions and uses thereof | |
| NZ711188A (en) | Yeast-brachyury immunotherapeutic compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23863936 Country of ref document: EP Kind code of ref document: A2 |